Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01401998 · ClinicalTrials.gov registry record
ARPKD Database Study
A clinical trial of Bardet-Biedl Syndrome and Autosomal Recessive Polycystic Kidney Disease, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- 200
- Enrollment target
- 6
- Study locations
NCT01401998: Recruiting study of Bardet-Biedl Syndrome and Autosomal Recessive Polycystic Kidney Disease, sponsored by Children's Hospital of Philadelphia.
NCT01401998 is a study of Bardet-Biedl Syndrome and Autosomal Recessive Polycystic Kidney Disease that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 200 participants. The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01401998, a study of Bardet-Biedl Syndrome and Autosomal Recessive Polycystic Kidney Disease, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 6
- Study locations
Study Summary
Hepato-renal fibrocystic diseases (HRFD) is a term developed that encompasses rare diseases such as Autosomal Recessive Polycystic Kidney Disease (ARPKD), and other diseases with common features (Joubert syndrome, Bardet Biedl syndrome, Meckel-Gruber syndrome, congenital hepatic fibrosis (CHF), Caroli syndrome (CS), polycystic liver disease, oro-facial-digital syndrome, nephronophithisis (NPHP), and glomerulocystic Kidney Disease). The lack of enough routinely available resources for these diseases to be well diagnosed and treated, would be best resolved by coordinated case accrual and sharing of clinical data and bio-specimens (DNA and tissues) among participating institutions, thereby leading to the centralization and sharing of clinical and genetic information, as well as bio-materials, providing an important engine for more rapid research progress and community understanding through the creation of research networks. This study aims to build a registry of a clinical database (medical health information), a mutational database (genetic information) and an educational resource about HRFD to eventually provide information about these diseases to families, physicians and genetic counselors via our existing HIPAA- approved study website. Goals for the Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource are: 1. \- Clinical Database: • Expand our comprehensive Clinical Database to include information from all patients who meet the inclusion criteria for hepato/renal fibrocystic diseases. 2. \- Mutational Database: * Test children with ARPKD and other hepato/renal fibrocystic disease to identify genetic mutations, establish a DNA bank for patients with hepato/renal fibrocystic diseases and develop a Mutational Database. This Database will be capable of linking clinical and mutational information via a unique identifier in a searchable format to facilitate genetic research (e.g. genotype-phenotype correlations, new disease gene studies, and m
Primary Outcome
Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource: The aims of this Core are: * Expand our current clinical and mutational database and establish a DNA bank * Establish a national tissue repository for hepato/renal fibrocystic diseases * Broaden the portfolio of educational tools developed for physicians and patients to encompass the hepato/renal fibrocystic diseases spectrum of disorders. A unique aspect of this Core is that it builds on established clinical, genotyping, a
Conditions Studied
Study Locations (6)
District of Columbia
- Children's National Hospital - Washington D.C.
Georgia
- Emory - Atlanta
Massachusetts
- Boston Children's - Boston
Ohio
- Cincinnati Children's - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2011-06 |
| Est. Completion | 2030-12 |
What NCT01401998 shows while recruiting
NCT01401998 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 10 conditions, with Bardet-Biedl Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT01401998 lists 6 locations in 6 states (District of Columbia, Georgia, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT01401998 about?
NCT01401998 is a clinical study titled "ARPKD Database Study". Hepato-renal fibrocystic diseases (HRFD) is a term developed that encompasses rare diseases such as Autosomal Recessive Polycystic Kidney Disease (ARPKD), and other diseases with common features (Joubert syndrome, Bardet Biedl syndrome, Meckel-Gruber syndrome, congenital hepatic fibrosis (CHF), Caro...
What is the current status of trial NCT01401998?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2011-06. Estimated completion is 2030-12.
What conditions does trial NCT01401998 study?
This clinical trial studies the following conditions: Bardet-Biedl Syndrome, Autosomal Recessive Polycystic Kidney Disease, Congenital Hepatic Fibrosis, Hepato/Renal Fibrocystic Disease, Joubert Syndrome.
Who is sponsoring clinical trial NCT01401998?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01401998 being conducted?
This trial has 6 study locations across District of Columbia, Georgia, Massachusetts, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bardet-Biedl Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia